Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03792841 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 212
- Enrollment target
NCT03792841 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 212 participants.
The verdict
NCT03792841, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 212 participants
- Enrollment target
Study Summary
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant prostate cancer, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Interventions
- DRUG Pembrolizumab
- DRUG Etanercept
- DRUG acapatamab
- DRUG Cytochrome P450 (CYP) Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2019-02-05 |
| Est. Completion | 2023-06-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03792841
The ClinicalTrials.gov registry entry for NCT03792841 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03792841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03792841 about?
NCT03792841 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC". A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant prostate cancer, and to determine the maximum tolerated dose (MTD) or rec...
What is the current status of trial NCT03792841?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 212 participants. The study started on 2019-02-05. Estimated completion is 2023-06-29.
What interventions are being tested in trial NCT03792841?
The interventions under investigation include: Pembrolizumab (DRUG), Etanercept (DRUG), acapatamab (DRUG), Cytochrome P450 (CYP) Cocktail (DRUG).
Who is sponsoring clinical trial NCT03792841?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.